CA
ACAD icon

CoreCap Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

CoreCap Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101 Buy
+4
New +$88 ﹤0.01% 3074
2026
Q1 		– Sell
-15,366
Closed -$410K – 2937
2025
Q4 		$410K Sell
15,366
-2,956
-16% -$70.6K 0.01% 560
2025
Q3 		$391K Buy
+18,322
New +$433K 0.01% 585

Other funds holding ACAD

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
GI
Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

CoreCap Advisors's ACAD Position: Q2 2026 in Review

CoreCap Advisors opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 4 shares worth $101. The stake represents ﹤0.01% of the portfolio and ranks #3074 among its holdings. This is a return to the name: CoreCap Advisors previously reported a position in ACAD as recently as Q4 2025.

CoreCap Advisors first reported a position in ACAD in Q3 2025 and has held it in 3 quarters since. The position peaked at $410K in Q4 2025. 29 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • CoreCap Advisors held 4 shares of Acadia Pharmaceuticals worth $101 as of Q2 2026.
  • Acadia Pharmaceuticals was a new CoreCap Advisors position in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #3074 holding.
  • CoreCap Advisors first reported a position in Acadia Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • CoreCap Advisors's Acadia Pharmaceuticals position peaked at $410K in Q4 2025.
  • 29 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.